328 related articles for article (PubMed ID: 26981507)
1. Recurrent Glioblastoma: Where we stand.
Roy S; Lahiri D; Maji T; Biswas J
South Asian J Cancer; 2015; 4(4):163-73. PubMed ID: 26981507
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma multiforme: overview of current treatment and future perspectives.
Anton K; Baehring JM; Mayer T
Hematol Oncol Clin North Am; 2012 Aug; 26(4):825-53. PubMed ID: 22794286
[TBL] [Abstract][Full Text] [Related]
3. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
5. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
[TBL] [Abstract][Full Text] [Related]
6. Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.
Hasan S; Chen E; Lanciano R; Yang J; Hanlon A; Lamond J; Arrigo S; Ding W; Mikhail M; Ghaneie A; Brady L
Front Oncol; 2015; 5():106. PubMed ID: 26029663
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
8. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
9. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
10. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Radiosurgery for Glioblastoma.
Redmond KJ; Mehta M
Cureus; 2015 Dec; 7(12):e413. PubMed ID: 26848407
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
Combs SE; Widmer V; Thilmann C; Hof H; Debus J; Schulz-Ertner D
Cancer; 2005 Nov; 104(10):2168-73. PubMed ID: 16220556
[TBL] [Abstract][Full Text] [Related]
13. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
Jindal V
Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
[TBL] [Abstract][Full Text] [Related]
14. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Curcumin in the Treatment of Glioblastoma Multiforme.
Shahcheraghi SH; Zangui M; Lotfi M; Ghayour-Mobarhan M; Ghorbani A; Jaliani HZ; Sadeghnia HR; Sahebkar A
Curr Pharm Des; 2019; 25(3):333-342. PubMed ID: 30864499
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
17. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
[TBL] [Abstract][Full Text] [Related]
18. Emerging Cellular Therapies for Glioblastoma Multiforme.
Choi PJ; Tubbs RS; Oskouian RJ
Cureus; 2018 Mar; 10(3):e2305. PubMed ID: 29755901
[TBL] [Abstract][Full Text] [Related]
19. Immune check-point in glioblastoma multiforme.
De Felice F; Pranno N; Marampon F; Musio D; Salducci M; Polimeni A; Tombolini V
Crit Rev Oncol Hematol; 2019 Jun; 138():60-69. PubMed ID: 31092387
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]